Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	12/13/2005 7:43:10 AM
	of 590

CURAGEN Announces Preliminary Top-line Phase II Results on Velafermin Tuesday December 13, 7:00 am ET -- Conference call scheduled for 11:00 a.m. EST to discuss results -- BRANFORD, Conn., Dec. 13 /PRNewswire-FirstCall/ -- CURAGEN Corporation(Nasdaq: CRGN - News) reported today preliminary top-line results from its Phase II randomized, placebo-controlled clinical trial evaluating a single-dose of velafermin for the prevention of oral mucositis (OM) in patients receiving high-dose chemotherapy, with or without total body irradiation, prior to autologous bone marrow transplantation. Analysis of this dose-ranging study showed a reduction in oral mucositis incidence in one of the three velafermin dose arms compared to placebo, although the primary endpoint, as evaluated by a predefined dose trend analysis did not reach statistical significance. Preliminary analysis of the 30-day safety results indicates that velafermin appears to be safe and well-tolerated in this severely ill patient population. Message 21967772

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next